HIV

The (Future) Doctor Is In

Medical Students Enjoy a Year at NIH

NIH MRSP participant Quashawn Chadwick

Every physician spends years in school getting trained to provide healthcare to patients with a wide array of health conditions, but not all of them know much about how the tools they use and the treatments they offer make it from the lab to the clinic. For the past year, 42 medical students took time off from their studies to fill in that gap first-hand by working in IRP labs as part of NIH’s Medical Research Scholars Program. As their stints at NIH wind down, each of them will return to medical school with valuable scientific training that will surely enhance their ability to help patients in the future. Keep reading to see how the MRSP has given a leg up to three of these bright future doctors.

Attacking HIV At Its Core

IRP Researchers are Developing Vaccines Targeting the ‘Achilles Heel’ of a Wiley Infectious Threat

DNA molecule surrounded by viruses

In the 40 years since HIV, the virus behind AIDS, was first definitively identified, treatments have changed the disease from a sure death to a long-term chronic illness. Yet, as we passed the 36th annual commemoration of World AIDS Day on December 1, it remains a dangerous health threat. Consequently, many researchers are attempting to develop vaccines to prevent or treat HIV, including IRP senior investigator Barbara K. Felber, Ph.D. Dr. Felber has been pursuing an effective vaccine since the discovery of HIV in the early 1980s using a unique approach that is not only making headway toward that important goal, but also offering insights into other infectious diseases, as well as cancer immunotherapy.

A History of NIH in 12 Objects

Lecture Explains Trinkets’ Links to Important Milestones

watch fob

The history of NIH and its precursor institution, the Hygienic Laboratory, stretches back nearly 140 years — way longer than any human being has ever lived. Even when those who have witnessed history are still around, the fading of memories threatens to erase our knowledge of the past. Fortunately, with proper storage and care, objects like those in the collections of the Office of NIH History and Stetten Museum can last hundreds of years, providing enduring reminders of important historical milestones.

On December 11, Stetten Museum curator Michele Lyons used a dozen such objects to describe the evolution of NIH from its origins to the modern day. Her presentation touched on topics ranging from NIH’s founding in New York to its key role in creating national standards for heart valve replacement surgery to the American AIDS crisis of the 1980s and 1990s.

HHS Awards Recognize IRP Cancer Researchers

Long Careers at NIH Yield Groundbreaking Achievements

from left to right: Dr. Robert Yarchoan, Dr. Elaine Jaffe, and Dr. Louis Staudt

When you work at the National Institutes of Health, major advances in health and science can seem like a regular occurrence. Yet not all advances are created equal; some change entire paradigms for understanding and treating disease, even disarming a disease’s lethal effects.

This fall, three IRP senior investigators received Departmental Awards from the United States Department of Health and Human Services (HHS) for their exceptional contributions to science: Louis M. Staudt, M.D., Ph.D., Elaine S. Jaffe, M.D., and Robert Yarchoan, M.D. Dr. Staudt received the HHS Secretary’s Award for Distinguished Service for his revolutionary work on the diagnosis and treatment of diffuse large B-cell lymphoma (DLBCL); Dr. Jaffe received the Secretary’s Award for Meritorious Service for her pioneering discoveries about lymphomas and blood cancers; and Dr. Yarchoan received the HHS Career Achievement Award for his role in developing the first effective drugs for AIDS and developing treatments for HIV-associated cancers.

Antibody Assault Shows Promise Against Dormant HIV

Treatment Strategy Could Mop Up Virus Hiding in Patients’ Bodies

antibodies attacking a virus

As temperatures drop in the fall, a variety of species from groundhogs to bears prepare to wait out the winter in their dens. Much like these animals, HIV also goes into hibernation when conditions are tough, a trait that has long stymied efforts to develop a cure. However, IRP researchers recently tested a promising strategy that might one day be used to flush out and kill dormant remnants of HIV.

IRP Research Yields Life-Changing Treatments

Highlighting Drugs and Vaccines Stemming from NIH Discoveries

syringe and vials of medicine

On May 3, more than six decades of IRP research culminated in the U.S. Food and Drug Administration (FDA) approving the world’s first vaccine for respiratory syncytial virus (RSV), a disease that puts tens of thousands of Americans in the hospital each year and kills thousands. While the new vaccine, called Arexy, has been getting all the headlines recently, it is only the latest example of a slew of FDA-approved medications and vaccines that might never have existed without the tireless efforts of scientists at NIH.

Indeed, a recently published study led by Mark Rohrbaugh, Ph.D., J.D., a special advisor in the NIH Office of Science Policy, found that inventions developed at NIH have contributed to more FDA-approved products than those created at any other nonprofit research institution in the world over the past five decades. NIH tops the study’s list with 27 FDA-approved products, six more than the study attributed to the combined efforts of all the schools in the University of California system.

Teaming Up to Tackle Engineering Challenges

Innovation Awards Accelerate Development of New Research Techniques

scientist working with a robotic arm

Scientists spend years, even decades, intensely studying a specific disease or biological system, an approach that yields unrivaled knowledge. However, many important scientific questions require a deep understanding of several subjects. As a result, the IRP has numerous programs dedicated to encouraging scientists with different areas of expertise to work together.

One such program is the NIH Director’s Challenge Innovation Awards, which funds innovative, high-impact projects that require the cooperation of researchers in more than one of NIH’s Institutes and Centers. This year, the program selected six promising proposals with one foot in the disciplines of biology and medicine and another in engineering or the physical sciences.

Understanding the Foundations of Immune Defenses

IRP’s Mary Carrington Elected to the American Academy of Arts and Sciences for Insights Into Immune System Variations

Dr. Mary Carrington

Some people never seem to get sick, while others catch a new bug of some sort every other week. Humans are immensely variable both in their capacity to shrug off illness and in the ways their bodies respond to medical treatments. IRP senior investigator Mary Carrington, Ph.D., has spent her entire career exploring the biological roots of these differences, and the discoveries she has made earned her election to the American Academy of Arts and Sciences earlier this year.

Leading the Charge Against Infectious Disease

Government Awards Recognize H. Clifford Lane’s Four Decades of Research Achievements

Dr. H. Clifford Lane

The remarkable career of H. Clifford Lane, M.D., might have gone very differently if a NIH scientist hadn’t accidentally eavesdropped on Dr. Lane’s conversation with a colleague in 1979. After hearing Dr. Lane mention that he had missed the deadline to apply for a position at NIH, the NIH researcher made some calls and discovered a spot there had just opened up — one that was perfect for Dr. Lane, who would spend the ensuing decades conducting life-saving research to understand and combat some of the world’s most dangerous infectious diseases.

Now the Clinical Director at the National Institute for Allergy and Infectious Disease (NIAID), Dr. Lane has been named a finalist for the 2022 Samuel J. Heyman Service to America Medals’ Career Achievement Award in recognition of his crucial contributions to the fight against HIV/AIDS, Ebola, COVID-19, and other illnesses. Also known as the “Sammies,” the awards recognize federal employees who are “breaking down barriers, overcoming huge challenges, and getting results.”

NIH Mourns the Passing of Thomas A. Waldmann

Dr. Thomas A. Waldmann

The NIH community is profoundly saddened by the recent passing of Thomas A. Waldmann, M.D., Chief Emeritus of the Lymphoid Malignancies Branch and NIH Distinguished Investigator.

Considered a giant in the field, Tom was a renowned immunologist whose more than 60-year career at the National Cancer Institute led to numerous high-impact discoveries that advanced the fields of organ transplantation, autoimmune disease and cancer. He was a leader in the study of cytokines and their receptors and of monoclonal antibodies, now a dominant form of cancer immunotherapy.